Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab
Booster vaccinations against SARS-CoV-2 are recommended 6–12 months after the last dose or infection in elderly and high-risk groups. The present analysis aims to evaluate whether an interval shorter than 12 months is required in multiple sclerosis patients receiving ofatumumab. Neutralizing antibod...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Taylor & Francis Group
2024-12-01
|
| Serie: | Human Vaccines & Immunotherapeutics |
| Soggetti: | |
| Accesso online: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2316422 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|